For Q1 FY2026 ended March 31, 2026, Tyra Biosciences reported no revenue. Net loss was $39.3 million, a 39.6% increase from the prior year. Operating loss was $42.0 million, up 31.9% year-over-year. Diluted EPS was -$0.64, a 36.2% decline from the prior year.
•Net loss of $39.3 million, up 39.6% YoY.
•Operating loss of $42.0 million, up 31.9% YoY.
•Diluted EPS of -$0.64, down 36.2% YoY.
•Cash of $85.0 million and equity of $387.6 million as of quarter end.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Tyra Biosciences, Inc., a clinical-stage biotechnology company develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and solid tumors.
The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and FGFR3-driven genetic syndromes. Its portfolio also includes TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma, and TYRA-430 for the treatment of hepatocellular carcinoma. Incorporated in 2018, Tyra Biosciences is headquartered in Carlsbad, California.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting fibroblast growth factor receptor (FGFR) biology. The company leverages its SNÅP platform, which uses iterative molecular snapshots to predict genetic alterations and design therapies for oncology and genetically defined conditions. Its lead product candidate, FGFR3, is in clinical trials for metastatic urothelial carcinoma and solid tumors. Additionally, Tyra is developing TYRA-300 for skeletal conditions such as achondroplasia and hypochondroplasia, TYRA-200 for intrahepatic cholangiocarcinoma, and TYRA-430 for hepatocellular carcinoma. The company operates solely in the United States.
On which stock exchange is Tyra Biosciences (TYRA) listed and what currency is used?
Tyra Biosciences is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol TYRA. Its shares are traded in U.S. dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, it is subject to the exchange's listing standards and regulatory requirements. Investors can buy and sell TYRA shares through brokerage accounts that have access to U.S. equity markets.
What sector and industry does Tyra Biosciences (TYRA) belong to?
Tyra Biosciences operates within the Healthcare sector, specifically in the Biotechnology industry. Biotechnology companies like Tyra focus on using biological processes and living organisms to develop medical treatments and diagnostics. As a clinical-stage biotech firm, Tyra is primarily engaged in research and development of precision medicines, with a particular emphasis on FGFR-targeted therapies for various cancers and genetic skeletal disorders. The company's work involves advanced drug design and clinical trials, which are characteristic of the biotechnology industry.
Where is Tyra Biosciences (TYRA) headquartered and what markets does it serve?
Tyra Biosciences is headquartered in Carlsbad, California, United States. The company was incorporated in 2018 and operates primarily within the U.S. market. Its research and development activities, including clinical trials for its product candidates, are conducted in the United States. While the company's focus is on developing therapies for global health conditions such as cancer and skeletal disorders, its current operations and market presence are centered in the U.S. There is no indication of international expansion or operations outside the United States based on available data.
What are the main product candidates in Tyra Biosciences' (TYRA) pipeline?
Tyra Biosciences has a pipeline of precision medicine candidates targeting FGFR biology. Its lead candidate, FGFR3, is in clinical trials for metastatic urothelial carcinoma and solid tumors. The company is also developing TYRA-300 for skeletal conditions including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes. Additionally, TYRA-200 is being investigated for intrahepatic cholangiocarcinoma, a type of bile duct cancer, and TYRA-430 is in development for hepatocellular carcinoma, the most common form of liver cancer. These candidates are supported by the company's SNÅP platform, which enables iterative drug design based on genetic alterations.